Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDC Recommends Reinstating Third Prevnar Dose For Healthy Children

This article was originally published in The Pink Sheet Daily

Executive Summary

The Centers for Disease Control & Prevention states that the fourth dose of the pneumococcal conjugate vaccine should continue to be deferred until supply is adequate. Wyeth will assist physicians with a "call-back" strategy to vaccinate children who had their third dose deferred.

You may also be interested in...



Prevnar Full Dose Schedule Restored By CDC

The Centers for Disease Control & Prevention reinstates four-dose recommendation for Wyeth’s pneumococcal conjugate vaccine. CDC recommended deferring the third and fourth doses earlier this year because of ongoing supply problems.

Prevnar Full Dose Schedule Restored By CDC

The Centers for Disease Control & Prevention reinstates four-dose recommendation for Wyeth’s pneumococcal conjugate vaccine. CDC recommended deferring the third and fourth doses earlier this year because of ongoing supply problems.

Prevnar Recommendation Will Be Restored “Very Soon”

The Centers for Disease Control & Prevention is on track to reinstate normal dosing recommendations for the pneumococcal conjugate vaccine Prevnar in the near future, Wyeth CEO Robert Essner indicated during the Bear Stearns meeting Sept. 14.

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel